COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success

Shefner, J. M., Al-Chalabi, A., Andrews, J. A., Chio, A., De Carvalho, M., Cockroft, B. M., Corcia, P., Couratier, P., Cudkowicz, M. E., Genge, A., Hardiman, O., Heiman-Patterson, T., Henderson, R. D., Ingre, C., Jackson, C. E., Johnston, W., Lechtzin, N., Ludolph, A., Maragakis, N. J., … Rudnicki, S. A. (2023). COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 24(5–6), 523–534. https://doi.org/10.1080/21678421.2023.2216223
Authors:
Jeremy M Shefner
Ammar Al-Chalabi
Jinsy A Andrews
Adriano Chio
Mamede De Carvalho
Bettina M Cockroft
Philippe Corcia
Philippe Couratier
Merit E Cudkowicz
Angela Genge
Orla Hardiman
Terry Heiman-Patterson
Robert D Henderson
Caroline Ingre
Carlayne E Jackson
Wendy Johnston
Noah Lechtzin
Albert Ludolph
Nicholas J Maragakis
Timothy M Miller
Jesus S Mora Pardina
Susanne Petri
Zachary Simmons
Leonard H Van Den Berg
Lorne Zinman
Stuart Kupfer
Fady I Malik
Lisa Meng
Tyrell J Simkins
Jenny Wei
Andrew A Wolff
Stacy A Rudnicki
Affiliated Authors:
Jinsy A Andrews
Subjects:
Author Keywords:
alsfrs-r
amyotrophic lateral sclerosis
randomized clinical trial
reldesemtiv
Publication Type:
Article
Unique ID:
10.1080/21678421.2023.2216223
PMID:
Publication Date:
Data Source:
PubMed

Record Created: